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This pilot study evaluated the influence of age and ethnicity on 
serum prostate-specific antigen (PSA) concentration in Asian 
and white men without a clinical diagnosis of prostate cancer. 
Between October and December 1993, 1260 patients who 
underwent serum PSA determination (Hybritech Tandem-R as-
say, San Diego, California) at Straub Clinic & Hospital were 
retrospectively analyzed. Of these, 885 {70%) men aged 40 to 79 
years were either Asian {Chinese, Filipino, Japanese, and Ko-
rean) or white and had a serum PSA less than 10.0 ng/ml. The 
PSA for the entire group was 2. 1 +I- 2. 0 ng/ml (mean +I- SO). PSA 
correlated with age (r=0.31, p=0.0001) and age accounted for 
10% of the variance in serum PSA. Using the regression formula, 
serum PSA increased 2.5% (0.06 ng/ml) per year of age. The 
entire study group was about equally divided between whites (49%) and Asians {51%). Nearly three-fourths of the Asian men 
were Japanese. The mean PSA was very close in the Asian and 
white groups. There was no direct correlation between serum 
PSA and ethnicity (r=0.03; p=0.3201). Ethnicity contributed 
0. 1% of the variance in PSA. In conclusion, this preliminary study 
suggests serum PSA increases with age in Asian and white men 
without a clinical diagnosis of prostate cancer. No difference 
was found in PSA between men of Asian and white ethnicity. 
Introduction 
Prostate carcinoma is an increasing medical problem in the 
United States. Prostate cancer is the most frequent nonskin 
cancer among men in the U.S., with 244,000 new cases and 
40,400 deaths estimated for 1995. 1 In Hawaii, 790 new cases and 
140 deaths are estimated for this year. Prostate-specific antigen 
is a protease secreted almost exclusively by the prostate epithe-
lium. Blood levels are increased when normal glandular struc-
ture is disrupted by benign or malignant tumor, inflammation, or 
trauma due to cystoscopy or biopsy. The serum PSA level is 
directly proportional to tumor volume, with a greater increase 
per unit volume of cancer compared with benign prostatic 
hyperplasia. 2 However, PSA is not sufficiently sensitive or 
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specific to be the ideal method of screening for prostate cancer. 
Approximately 25% of men with benign prostatic hyperplasia 
have an elevated serum PSA level. 3-4 Conversely, not all prostate 
cancers give rise to an elevated serum PSA concentration. 
Approximately 40% of men with organ-confined prostate can-
cer who undergo radical prostatectomy for potential cure have 
a normal serum PSA value using the conventional reference 
range. 
The standard normal reference range for PSA (Hybritech 
Tandem-R assay, San Diego, California) is 0.0-4.0 ng/ml. 
Myrtle et al derived the upper limit of normal in a population of 
472 apparently healthy, asymptomatic men.5 No PSA values 
exceeded 10.0 ng/ml and 99% were less than 4.0 ng/ml. All men 
less than 40 years of age and 97% of men 40 years or older had 
a serum PSA less than or equal to 4.0 ng/ml. Recently Dalkin and 
co-workers conducted a study to refine the upper limits ofPSA 
by age in men older than 50 years.6 The new upper limits were 
3.5 ng/ml for the 50-59 year old group, 5.4 ng/ml in the 60-69 
year old, and 6.3 ng/ml in the 70-79 year old men. Oesterling and 
colleagues also suggested a revision with age-specific reference 
values for serum PSA. 7 The recommended upper normal values 
were 2.5 ng/ml for men 40-49 years, 3.5 ng/ml for 50-59 years, 
4.5 ng/ml for 60-69 years and 6.5 ng/ml for 70-79 years. 
The influence of ethnicity on serum PSA has not been well-
studied. Oesterling's study was limited to a population of white 
men. 7 The possible link between PSA and ethnicity is suggested 
by data demonstrating differences in incidence and death rates 
Fig. 1.-Mean serum prostate-specific antigen concentration 
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between Asian, black, Hispanic, and white populations. 1•8 As 
Asians represent the fastest growing minority group in the U.S., 
PSA normal value recommendations should be examined within 
the context of different ethnic groups in order to ascertain the 
effects of both age and ethnicity variables. This is especially 
important as the use of serum PSA values increasingly influence 
recommendations regarding referral and follow-up procedures 
for the diagnosis of prostate cancer. This pilot study was de-
signed to assess the influence of age and ethnicity on serum PSA 
concentrations in Asian and white men living in the U.S. without 
a clinical diagnosis of prostate cancer. 
Methods 
Patients 
Between October and December 1993, 1260 men who had 
serum PSA (Hybritech Tandem-R assay, San Diego, Califor-
nia) determinations at Straub Clinic & Hospital Department of 
Nuclear Medicine Radioimmunoassay Laboratory were ini-
tially identified as the cohort population. Patient name, age, and 
PSA concentration were obtained from the computer Labora-
tory Information System. The ethnicity of the patient was 
identified from the clinic and hospital computer demographic 
and schedule tracking system. The clinical diagnosis pertaining 
to disease of the prostate was obtained from review of each 
patient's clinic chart. Men who had a PSA value less than 10.0 
ng/ml and who had no diagnosis of prostate cancer were selected 
for analysis. Ethnic categories included Asian and white men. 
Asian included Japanese, Korean, Filipino, and Chinese. Those 
who had mixed ancestry among these groups were included as 
Asian. Those who had mixed ancestry between any of these 
Table 1.-8erum PSA Concentration and Patient Distribution 
by Age* 
Age Patient PSA 
(years) No. (ng/ml) 
40-49 71 1.03t (1.01, 1.06)t 
50-59 215 1.24 (1.23, 1.26) 
60-69 323 2.17 (2.16, 2.18) 
70-79 276 2.08 (1.68. 2.70) 
Total 885 2.08 (1.95. 2.21) 
'PSA indicates prostate-specrric antigen 
tMean value 
*Numbers in parenthesis are the lower and upper values for the 95% confidence interval 
Table 2.- Serum PSA Concentration by Age and Ethnicity* 
Asian White 
Age PSA PSA 
Group (ng/ml) 95%C.I. (ng/ml) 95%C.I. 
40-49 1.10t (1.03, 1.17)t 0.99t (0.94, 1.03)t 
50-59 1.13 (1.11, 1.15) 1.36 (1.34, 1.38} 
60-69 2.24 (2.22, 2.68) 2.09 (2.07, 2.11) 
70-79 2.66 (2.65, 2.68} 2.73 (2.71, 2.75} 
Total 210 (2.10, 2.11} 2.05 (2.05, 2.06} 
'PSA indicates prostate-specffic antigen 
tMean value 
*Numbers in parenthesis are the lower and upper values for the 95% confidence interval 
-
groups and other groups were not included in the study. Anyone 
with mixed ancestry between white and other groups was also 
not included. The final population sample consisted of 885 (70%) men aged 40 to 79 years. 
Statistical analysis 
Regression analysis was accomplished with the Statistical 
Analysis System (SAS) software, Regression Procedure, using 
the multiple regression and stepwise regression models with 
PSA as the predicted (dependent) variable and age and ethnicity 
as predictor (independent) variables. The PSA values were log 
(natural) transformed in order to better meet the linear assump-
tions of the regression model. The regression procedure calcu-
lated the Y intercept and the slope of the regression line. From 
this information it was possible to compute the predicted in-
crease in PSA per year of age, both in absolute and relative 
terms. The software also calculated the multiple regression 
coefficient squared which indicates the proportion of the vari-
ance in PSA that is accounted for by age and ethnicity. The SAS 
Correlation Procedure computed the Pearson product moment 
coefficients of correlation (rho). This allowed paired compari-
sons of PSA and age and PSA and ethnicity. A p=0.05 was 
considered significant. The SAS software also calculated PSA 
means by different age and ethnicity groups and determined the 
cross-tabulations used in the analysis with 95% confidence 
intervals. 
The mean + 2 SD was used as the upper limit of the estimated 
ranges for the serum PSA concentration for each 10-year age 
group. 
Results 
The PSA for the entire group of 885 men was 2.08 ± 2.0 ng/ml (mean+/- SD)(Table 1). The mean serum PSA concentration for 
each 10-year age group increased with age at the 95% level of 
confidence. Between 40-49 years, 2 (2.8%) had a serum PSA 
greater than 4.0 ng/ml; between 50-59 years, 5 (2.8% ); between 
60-69 years, 51 (15.8%); and between 70-79 years 69 (25.7%) 
had a serum PSA above 4.0 ng/ml. Overall, 127 men (14.7%) 
had a serum PSA greaterthan 4.0 ng/ml. PSA correlated with age (r=0.31; p=0.0001). Age accounted for 10% of the variance in 
serum PSA (p=0.0001). Using the regression formula, serum 
PSA increased 2.5% (0.06 ng/ml) per year of age. 
The study group was about equally divided between white ( 49%) and Asian (51%) cases. Nearly three-fourths of the Asian 
men were of Japanese ethnicity. There was no direct correlation 
between serum PSA andethnicity (r=0.03; p=0.3201). Ethnicity 
accounted for only 0.1% of the variance in PSA. Mean serum 
PSA for each age-specific group increased with age in both the 
Asian and white men (Fig 1). For age groups 40-49 and 60-69 
years, mean PSA for the Asian cases was higher than white at the 
95% level of confidence; for age groups 50-59 and 70-79 years, 
for white men were higher than Asian (Table 2). The age and 
ethnic-specific serum PSA ranges are shown in Table 3. 
Discussion 
Reference ranges for serum PSA in the published literature 
were derived from various populations of healthy men without 
clinically evident prostate cancer. 5-7 The validity of these param-
eters for the detection of early, and potentially curable prostate 
cancer have not been well-studied among the Asians. A possible 
link between PSA and ethnicity was suggested by a study 
conducted by Christmas, where the incidence of prostate cancer 
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Table 3.-serum PSA Ranges by Age and Ethnicity* 
Total Asian White 
Age PSA PSA PSA 
Group (ng/ml) S.D. Range (ng/ml) S.D. Range (ng/ml) S.D. Range 
40-49 1.0t 0.7 0.0 -2.4t 1.1t 0.7 0.0- 2.6t 1.0t 0.6 0.0-2.2t 
50-59 1.2 1.0 0.0-3.3 1.1 0.8 0.0-2.7 1.4 1.3 0.0-3.9 
60-69 2.2 2.0 0.0-6.1 2.2 2.0 0.0-6.2 2.1 1.9 0.0-5.9 
70-79 2.7 2.3 0.0-7.2 2.7 2.2 0.0-7.0 2.7 2.4 0.0-7.4 
All Ages 2.1 2.0 0.0-6.0 2.1 1.9 0.0-60 2.1 2.0 0.0-6.0 
'PSA indicates prostate-specific antigen tMean value *Range upper limit is mean+ 2 S.D. 
The study population was selected 
from an arbitrary fixed time frame. This per-
mitted a sample of the large patient popula-
tion at the clinic and hospital undergoing a 
PSA test. The inherent biases of the cross-
sectional study applied across the Asian and 
white groups and still permitted a valid com-
parison of the two groups. The inclusion of 
men with a PSA greater than 4.0 ng/ml but 
with prostate cancer not yet diagnosed could 
inflate the calculated mean PSA values and 
ranges; the effect on the correlation and re-
gression analysis values would be slight in the 
estimation of the authors. 
was shown to be particularly common among blacks in the U.S. 
and among Scandinavians, but rare among Japanese and other 
Asians. 8 More recent cancer statistics show that age-adjusted 
death rates for prostate cancer reported between 1988-1991 
were highest in Switzerland, Sweden, and Norway and lowest in 
Japan, Hong Kong, and China. 1 
The increase in PSA with age demonstrated in this study has 
been observed by other investigators. s-w There was no consistent 
difference in serum PSA between Asian and white men without 
a clinical diagnosis of prostate cancer. PSA did not correlate 
with ethnicity (r=0.03, p=0.3210) and ethnicity was not predic-
tive ofPSA (0.1% of the variance). From a practical standpoint, 
the mean PSA levels were nearly identical overall for the Asian 
and white men. The age-specific range ofPSA values for the two 
ethnic groups were very similar. Statistical differences between 
Asian and white PSA levels fluctuated for the age-specific 
groups and there was no consistent trend. 
The retrospective, cross-sectional nature of our study is inap-
propriate for deriving reference ranges for PSA concentrations. 
Although patients with a diagnosis of prostate cancer were 
excluded from the study, the sample population cannot be 
considered healthy and prostate cancer-free. The fraction of 
patients with an abnormal PSA using the conventional cutoff 
value of 4.0 ng/ml and no clinical evidence of cancer by digital 
rectal examination (DRE), transrectal ultrasonography (TRUS), 
and prostate biopsy is unknown. In addition, patients with a 
normal DRE and PSA cannot be excluded from harboring 
prostate cancer. The significant expense ofTRUS makes its use 
in the routine evaluation of patients with normal PSA and DRE 
impractical in the clinical practice at the study institution. 
The investigators ofthis study attempted to decrease the level 
of uncertainty of undiagnosed prostate cancer cases by exclud-
ing patients with PSA greater than I 0 ng/ml in our final analysis. 
The rationale for this rests on the observation that individuals 
with such values distort the true population of normal men at 
large. 9 In addition, men with values substantially greater than 10 
ng/ml, and certainly values reaching the hundreds, have a higher 
likelihood of prostatic cancer. 6•10 
Data on patient prostate size were not in-
cluded in this study. Adjustment of the serum PSA for the size 
of the prostate gland may help to distinguish men with early 
prostate cancer from those with benign prostatic hypertrophy .11 
An ancillary study proposal to the National Cancer Institute 
Prostate, Lung, Colon, and Ovary cancer screening trial evalu-
ating the the relationship between PSA, prostate size, and 
ethnicity in patients from Hawaii was recently approved for the 
investigators of this study. 
Serum PSA is currently the most useful tumor marker for the 
diagnosis of prostate cancer, and is a potentially important 
screening test. Intensive efforts by researchers to identify cost-
effective screening strategies incorporating the PSA test are 
ongoing. This preliminary study contributes to the understand-
ing of PSA variation among individuals at risk for prostate 
malignancy with respect to ethnicity. 
In summary, PSA increases with age in Asian and white men 
without a clinical diagnosis of prostate cancer but who are at risk 
for malignancy. No apparent difference was found in serum PSA 
between Asian and white men. 
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